Cell Therapeutics (CTIC)
Q2 2012 Earnings Call
August 01, 2012 8:30 am ET
James A. Bianco - Principal Founder, Chief Executive Officer, President and Executive Director
Louis A. Bianco - Co-Founder, Principal Financial Officer, Principal Accounting Officer, Executive Vice President - Finance and Administration and Secretary
Steven E. Benner - Chief Medical Officer and Executive Vice President
Michael G. King - Rodman & Renshaw, LLC, Research Division
Ladies and gentlemen, thank you for standing by. Welcome to the Cell Therapeutics Q2 Financial Results Call on the 1st of August, 2012. [Operator Instructions] I would now like to hand the conference over to Dr. James Bianco, President and CEO. Please go ahead, sir.
James A. Bianco
Good morning. Thank you for joining us today. Before I get started, I'd like to remind you, as is common with presentations of this type, that we'll be making forward-looking statements, and as such, I recommend you refer to our SEC filings for more information on the company.
Let me also remind you that this call is recorded and be available for playback on our website. Any unauthorized recording of this call or use of this recording is prohibited without written consent of the company.
So on today's call, we're going to review the financial results for the second quarter, update you on our prelaunch activities and in-market research on a potential commercial opportunity on Pixuvri, talk about the status of the pacritinib Phase III program and review the strategy for tosedostat and briefly discuss the activities on OPAXIO and brostallicin. Let me start with the financial results for the second quarter.
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts